12,000 Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Bought by Quarry LP

Quarry LP purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,000 shares of the biotechnology company’s stock, valued at approximately $108,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $25,000. Tower Research Capital LLC TRC increased its stake in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 2,635 shares during the period. Natixis acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $49,000. Blue Trust Inc. increased its stake in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $90,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:AUPH opened at $8.12 on Wednesday. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -54.13 and a beta of 1.20. The firm’s 50-day simple moving average is $8.01 and its 200-day simple moving average is $8.16. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $10.67.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, CEO Peter Greenleaf sold 195,593 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the sale, the chief executive officer now owns 1,953,892 shares of the company’s stock, valued at $15,631,136. This represents a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Greg Keenan sold 8,305 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares in the company, valued at $1,263,173.32. This represents a 5.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 343,898 shares of company stock valued at $2,753,094. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.